NCT04732871: Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
- State
- Under way
- Phase
- Phase 3
- People
- 1,720 taking part
- Started
- 15 Feb 2021
- Primary completion
- 6 Jun 2022
- Arms
- RSV_annual Group, RSV_Flexible revaccination Group, RSV_1dose Group
- Results
- Posted on the registry
- 1 Feb 2021: Trial registered
- 15 Feb 2021: Trial started
- 21 Dec 2023: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1
Primary outcome · Geometric mean, Titers (ED60) · At Day 1
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 342 | 832.4 (95% Confidence Interval 763.4 to 907.7) |
| RSV_flexible Revaccination | 321 | 864.9 (95% Confidence Interval 790.6 to 946.1) |
| RSV_1dose | 319 | 896.8 (95% Confidence Interval 815.9 to 985.8) |
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31
Primary outcome · Geometric mean, Titers (ED60) · At Day 31
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 328 | 8827.2 (95% Confidence Interval 7905 to 9857) |
| RSV_flexible Revaccination | 300 | 8906.6 (95% Confidence Interval 7972.3 to 9950.3) |
| RSV_1dose | 309 | 9585.6 (95% Confidence Interval 8448.8 to 10875.5) |
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6
Primary outcome · Geometric mean, Titers (ED60) · At Month 6
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 319 | 3465.2 (95% Confidence Interval 3140.9 to 3823) |
| RSV_flexible Revaccination | 294 | 3600.1 (95% Confidence Interval 3242.2 to 3997.5) |
| RSV_1dose | 311 | 4223.1 (95% Confidence Interval 3795.3 to 4699) |
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12
Primary outcome · Geometric mean, Titers (ED60) · At Month 12
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 284 | 2529.9 (95% Confidence Interval 2274.5 to 2814) |
| RSV_flexible Revaccination | 291 | 2695.7 (95% Confidence Interval 2421.4 to 3001) |
| RSV_1dose | 296 | 2800.1 (95% Confidence Interval 2501.6 to 3134.3) |
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1
Primary outcome · Geometric mean, Titers (ED60) · At Day 1
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 342 | 1138.7 (95% Confidence Interval 1046.2 to 1239.3) |
| RSV_flexible Revaccination | 321 | 1325.9 (95% Confidence Interval 1206.9 to 1456.6) |
| RSV_1dose | 320 | 1258.7 (95% Confidence Interval 1142 to 1387.4) |
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31
Primary outcome · Geometric mean, Titers (ED60) · At Day 31
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 328 | 9219.7 (95% Confidence Interval 8368.7 to 10157.3) |
| RSV_flexible Revaccination | 300 | 9955.2 (95% Confidence Interval 9002.1 to 11009.3) |
| RSV_1dose | 309 | 9756.1 (95% Confidence Interval 8785.4 to 10834) |
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6
Primary outcome · Geometric mean, Titers (ED60) · At Month 6
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 319 | 3886.4 (95% Confidence Interval 3563.5 to 4238.6) |
| RSV_flexible Revaccination | 294 | 4484.6 (95% Confidence Interval 4063.8 to 4949) |
| RSV_1dose | 311 | 4570.6 (95% Confidence Interval 4152 to 5031.4) |
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12
Primary outcome · Geometric mean, Titers (ED60) · At Month 12
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 284 | 2671.4 (95% Confidence Interval 2433.3 to 2932.9) |
| RSV_flexible Revaccination | 291 | 3015.4 (95% Confidence Interval 2737.9 to 3321) |
| RSV_1dose | 296 | 2977.1 (95% Confidence Interval 2669.6 to 3320) |
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1
Secondary outcome · Geometric mean, ELU/mL · At Day 1
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 342 | 7334.7 (95% Confidence Interval 6868.3 to 7832.8) |
| RSV_flexible Revaccination | 320 | 7437.1 (95% Confidence Interval 6948.6 to 7959.9) |
| RSV_1dose | 320 | 7759 (95% Confidence Interval 7212.5 to 8346.8) |
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31
Secondary outcome · Geometric mean, ELU/mL · At Day 31
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 328 | 86929.7 (95% Confidence Interval 80662.7 to 93683.6) |
| RSV_flexible Revaccination | 300 | 92664.7 (95% Confidence Interval 86050.1 to 99787.8) |
| RSV_1dose | 309 | 94249.4 (95% Confidence Interval 87660.7 to 101333.3) |
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6
Secondary outcome · Geometric mean, ELU/mL · At Month 6
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 319 | 33855.9 (95% Confidence Interval 31405.3 to 36497.7) |
| RSV_flexible Revaccination | 294 | 35193.5 (95% Confidence Interval 32623.6 to 37965.9) |
| RSV_1dose | 311 | 36525.7 (95% Confidence Interval 33938 to 39310.7) |
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12
Secondary outcome · Geometric mean, ELU/mL · At Month 12
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 284 | 24733.5 (95% Confidence Interval 22994.3 to 26604.2) |
| RSV_flexible Revaccination | 291 | 26484.1 (95% Confidence Interval 24651.7 to 28452.8) |
| RSV_1dose | 296 | 27360.3 (95% Confidence Interval 25476.7 to 29383) |
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Day 1
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 287 | 202 (Inter-Quartile Range 83 to 376) |
| RSV_flexible Revaccination | 93 | 143 (Inter-Quartile Range 26 to 294) |
| RSV_1dose | 95 | 171 (Inter-Quartile Range 65 to 385) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Day 1
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 287 | 33 (Inter-Quartile Range 1 to 110) |
| RSV_flexible Revaccination | 93 | 32 (Inter-Quartile Range 1 to 103) |
| RSV_1dose | 95 | 2 (Inter-Quartile Range 1 to 107) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Day 31
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 245 | 1310 (Inter-Quartile Range 813 to 2155) |
| RSV_flexible Revaccination | 81 | 1292.5 (Inter-Quartile Range 820.5 to 2254) |
| RSV_1dose | 84 | 1570 (Inter-Quartile Range 876 to 1971) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Day 31
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 245 | 26 (Inter-Quartile Range 1 to 129) |
| RSV_flexible Revaccination | 81 | 58 (Inter-Quartile Range 1 to 143) |
| RSV_1dose | 84 | 5 (Inter-Quartile Range 1 to 101) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Month 6
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 263 | 662 (Inter-Quartile Range 428 to 1026) |
| RSV_flexible Revaccination | 87 | 644 (Inter-Quartile Range 442 to 1100) |
| RSV_1dose | 86 | 695 (Inter-Quartile Range 427 to 1131) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Month 6
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 248 | 38 (Inter-Quartile Range 1 to 113) |
| RSV_flexible Revaccination | 88 | 24.5 (Inter-Quartile Range 1 to 103.5) |
| RSV_1dose | 85 | 26 (Inter-Quartile Range 1 to 87) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Secondary outcome · Median, CD4 atl2_7m/ million of CD4+ cells · At Month 12
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 257 | 564 (Inter-Quartile Range 348 to 898) |
| RSV_flexible Revaccination | 94 | 525 (Inter-Quartile Range 345 to 818) |
| RSV_1dose | 92 | 671 (Inter-Quartile Range 374.5 to 1072.5) |
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
Secondary outcome · Median, CD8 atl2_7m/ million of CD8+ cells · At Month 12
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 257 | 1 (Inter-Quartile Range 1 to 81) |
| RSV_flexible Revaccination | 94 | 18 (Inter-Quartile Range 1 to 108) |
| RSV_1dose | 92 | 22 (Inter-Quartile Range 1 to 104) |
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1
Secondary outcome · Number of participants · During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
| Group | Analysed | Value |
|---|---|---|
| RSV_annual Erythema | 989 | 99 |
| RSV_flexible Revaccination Erythema | 328 | 38 |
| RSV_1dose Erythema | 328 | 22 |
| RSV_annual Pain | 989 | 595 |
| RSV_flexible Revaccination Pain | 328 | 201 |
| RSV_1dose Pain | 328 | 200 |
| RSV_annual Swelling | 989 | 75 |
| RSV_flexible Revaccination Swelling | 328 | 33 |
| RSV_1dose Swelling | 328 | 16 |
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1
Secondary outcome · Number of participants · During the 4-day follow up period after vaccination (vaccine administered on Day 1)
| Group | Analysed | Value |
|---|---|---|
| RSV_annual Arthralgia | 989 | 157 |
| RSV_flexible Revaccination Arthralgia | 328 | 49 |
| RSV_1dose Arthralgia | 329 | 49 |
| RSV_annual Fatigue | 989 | 307 |
| RSV_flexible Revaccination Fatigue | 328 | 100 |
| RSV_1dose Fatigue | 329 | 110 |
| RSV_annual Fever | 989 | 13 |
| RSV_flexible Revaccination Fever | 328 | 5 |
| RSV_1dose Fever | 329 | 7 |
| RSV_annual Headache | 989 | 187 |
| RSV_flexible Revaccination Headache | 328 | 70 |
| RSV_1dose Headache | 329 | 79 |
| RSV_annual Myalgia | 989 | 336 |
| RSV_flexible Revaccination Myalgia | 328 | 107 |
| RSV_1dose Myalgia | 329 | 109 |
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1
Secondary outcome · Number of participants · During the 30-day follow up period after vaccination (vaccine administered on Day 1)
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 993 | 125 |
| RSV_flexible Revaccination | 329 | 45 |
| RSV_1dose | 331 | 55 |
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1
Secondary outcome · Number of participants · From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 993 | 36 |
| RSV_flexible Revaccination | 329 | 16 |
| RSV_1dose | 331 | 15 |
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1
Secondary outcome · Number of participants · From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
| Group | Analysed | Value |
|---|---|---|
| RSV_annual | 993 | 0 |
| RSV_flexible Revaccination | 329 | 1 |
| RSV_1dose | 331 | 0 |